PensionDanmark Pensionsforsikringsaktieselskab Buys 38,596 Shares of Bristol Myers Squibb Company $BMY

PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 545,224 shares of the biopharmaceutical company’s stock after purchasing an additional 38,596 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Bristol Myers Squibb were worth $31,416,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth $25,000. Physician Wealth Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the 2nd quarter valued at about $25,000. Bayban acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY stock opened at $64.19 on Friday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.10. The company has a market capitalization of $131.13 billion, a P/E ratio of 14.14, a PEG ratio of 0.16 and a beta of 0.22. The company has a fifty day moving average price of $58.56 and a 200-day moving average price of $58.60.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.Bristol Myers Squibb’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.97 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst upgrades strengthen the outlook. Zacks upgraded BMY to Rank #2 (Buy), citing growing optimism about the company’s earnings prospects. Argus also raised its rating from “Hold” to “Buy” and set a $75 price target, implying further upside from recent levels. Bristol Myers Moves to Buy: Rationale Behind the Upgrade
• Positive Sentiment: Bristol Myers expanded its AI drug-discovery partnership with Schrödinger. Wider deployment of Schrödinger’s Bunsen and RetroSynth platforms across BMY’s research teams could improve drug-design efficiency and support the company’s longer-term pipeline, though the financial impact is not immediate. Schrödinger and BMS expand partnership
• Neutral Sentiment: Recent earnings momentum remains supportive. BMY previously reported earnings and revenue above analyst expectations, with revenue up year over year and full-year 2026 EPS guidance of $6.75-$7.00. This helps explain the stock’s strength and elevated investor interest.
• Neutral Sentiment: Alzheimer’s market developments offer limited direct benefit. The article highlights Leqembi and other disease-modifying therapies, but it does not identify a direct Bristol Myers product catalyst. Alzheimer’s Disease Market Pipeline Therapies
• Negative Sentiment: Merger speculation with AstraZeneca was denied. A senior source told Reuters there are “no discussions” regarding a potential transaction. That removes a possible takeover premium or strategic catalyst, although it also reduces uncertainty surrounding a major deal. No discussions over AstraZeneca-Bristol Myers deal

Analyst Upgrades and Downgrades

BMY has been the subject of several research reports. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday. Bank of America lowered their price objective on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Piper Sandler started coverage on Bristol Myers Squibb in a report on Wednesday. They set an “overweight” rating for the company. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, TD Cowen assumed coverage on shares of Bristol Myers Squibb in a research note on Wednesday. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $66.06.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.